On February 8, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the 2018 CAGNY Conference on Thursday, Feb. 22, at The Boca Raton Resort, Boca Raton, FL. Jorge Mesquita, Executive Vice President, Worldwide Chairman, Consumer and Alison Lewis, Chief Marketing Officer, Consumer will represent the Company in a session scheduled at 2:00 p.m. (Eastern Time) (Press release, Johnson & Johnson, FEB 8, 2018, View Source [SID1234523842]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately two hours after the live webcast.

REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 7, 2018 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, will present during the BIO CEO & Investor Conference next week in New York (Press release, Heat Biologics, FEB 7, 2018, View Source [SID1234523783]). Jeff Wolf, CEO of Heat, will present at 9 a.m. ET, on Tuesday, Feb. 13, 2018, and he will also be available to participate in one-on-one meetings with investors registered to attend the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BIO CEO & Investor Forum is a biotech investor conference focused on established and emerging, publicly traded and select private biotech companies. The event features plenary sessions, education sessions focused on therapeutic topics and business issues, company presentations, and one-on-one meetings.

On February 7, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, reported that David Hansen, MabVax’s President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY (Press release, MabVax, FEB 7, 2018, View Source [SID1234523784]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company’s two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients. The Company remains on track to announce interim safety and response data from the MVT-5873 study early in the first quarter of 2018; and (2) the MVT-1075 program, a human antibody-based radioimmunotherapy ("RIT") product, currently being evaluated in a Phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers. MabVax recently announced the completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 MVT-1075 study and plans to report interim results from this study in the first quarter of 2018.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the Company through the one-on-one meeting portal.

A live audio webcast of the presentation will be available on the Events page of the Investor section of the Company’s website (www.mabvax.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.

On February 7, 2017 Sanofi reported financial results for the fiscal year ended December 31, 2017 (Press release, Sanofi, FEB 7, 2018, View Source [SID1234523887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q4 2017 sales reflect strong Dupixent launch offset by anticipated declines in U.S. diabetes and Renagel

Net sales were €8,691 million, down 2.0% on a reported basis and up 4.1%(3) at CER. At CER/CS(3), net sales were down 1.6%.
Strong Sanofi Genzyme sales growth (up 16.8%) driven by contribution from new immunology franchise.
Sanofi Pasteur sales increased 1.2% at CER/CS impacted by order phasing effects and Dengvaxia.
CHC sales grew 2.5% at CER/CS.
Diabetes and Cardiovascular GBU sales down 19.1%.
Emerging Markets(4) sales increased 2.1% at CER/CS, driven by Pharmaceuticals which increased 4.0% at CER/CS.
Sanofi Genzyme, Sanofi Pasteur and Emerging Markets sales growth more than offset Diabetes sales decline in 2017

Net sales in 2017 were €35,055 million, up 3.6% on a reported basis and 5.6%(2) at CER. Net sales were up 0.5% at CER/CS.
Sanofi Genzyme grew 15.1% to €5,674 million while Sanofi Pasteur increased 8.3% (at CER/CS) to €5,101 million.
Emerging Markets sales were up 6.0% at CER/CS supported by strong performance in China (up 15.1% at CER/CS).
Diabetes and Cardiovascular GBU sales declined 14.3% to €5,400 million.
Sanofi meets its full-year 2017 business EPS guidance

Q4 2017 business EPS(1) decreased 8.8% at CER to €1.06, including financial impact from Dengvaxia (-€0.10).
2017 business EPS(1) of €5.54 (-0.4% at CER) and IFRS EPS of €6.71 (+83.3% on a reported basis).
Net debt was €5,229 million at the end of 2017, a decrease from €8,206 million at the end of 2016.
Board proposes dividend of €3.03, an increase of 2.4%.
2017 business net income (BNI) effective tax rate unaffected by the U.S. tax reform. In 2018, Sanofi expects the BNI effective tax rate to be around 22% primarily as a result of U.S. tax reform(5).
Sanofi progresses on its strategic priorities

Sanofi to acquire Bioverativ(6) for $11.6 billion to expand in specialty care and strengthen its leadership in rare diseases.
Sanofi to acquire Ablynx(6) for €3.9 billion to strengthen its R&D strategy with innovative Nanobody technology platform.
Agreement signed with Regeneron to accelerate and expand investments for the development of cemiplimab and dupilumab.
FDA supplemental BLA submission for dupilumab in uncontrolled persistent asthma for adults and adolescents.
2018 financial outlook

Sanofi expects 2018 business EPS(1) to grow between 2% and 5%(7) at CER, including the anticipated contribution from the recently announced acquisitions, barring unforeseen major adverse events. Applying the average December 2017 exchange rates, the currency impact on 2018 business EPS is estimated to be -3% to -4%.